(616 Kb) -

The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on:

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort

Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you? (616 KB)

: For those who stopped the medication, the median time until they did so was only 7 months .

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can: The authors argue that because the drug is

The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials : For those who stopped the medication, the

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC